MARKET

AVEO

AVEO

Aveo
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.32
+0.07
+1.33%
After Hours: 5.35 +0.03 +0.56% 17:15 02/21 EST
OPEN
5.22
PREV CLOSE
5.25
HIGH
5.35
LOW
5.03
VOLUME
275.62K
TURNOVER
--
52 WEEK HIGH
18.50
52 WEEK LOW
4.653
MARKET CAP
85.56M
P/E (TTM)
2.031
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of AVEO and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average AVEO stock price target is 19.17 with a high estimate of 20.00 and a low estimate of 17.50.

EPS

AVEO News

More
  • Aveo Oncology to reverse split stock today; shares down 10%
  • seekingalpha · 2d ago
  • AVEO Announces Effectiveness of 1-for-10 Reverse Stock Split
  • Business Wire · 3d ago
  • AVEO: Still A Speculative Buy Ahead Of FOTIVDA NDA Submission
  • Seeking Alpha - Article · 02/13 17:58
  • The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO
  • Benzinga · 02/13 13:05

Industry

Biotechnology & Medical Research
+0.37%
Pharmaceuticals & Medical Research
+0.54%

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

About AVEO

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's platform delivers insights into cancer and related disease. The Company's product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors. Tivozanib is designed to optimize VEGF blockade while minimizing off-target toxicities. Ficlatuzumab is a Hepatocyte Growth Factor (HGF) inhibitory antibody. AV-203 is an anti-ErbB3 monoclonal antibody with ErbB3 affinity. Its preclinical studies suggest that neuregulin1 (NRG1) levels predict AV-203 antitumor activity in preclinical models. AV-380 is a humanized Immunoglobulin G 1 (IgG1) inhibitory monoclonal antibody. AV-380 targets growth differentiating factor 15 (GDF15).
More

Webull offers kinds of AVEO Pharmaceuticals, Inc. stock information, including NASDAQ:AVEO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AVEO stock news, and many more online research tools to help you make informed decisions.